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Aims To determine whether valsartan improves treadmill exercise time, in patients with symptomatic heart failure with a
preserved ejection fraction (HFPEF), compared with placebo.
Methods
and results
In this multicentred, double-blind, 14-week study, patients were randomized to receive valsartan (V) 80 mg or
placebo (P) once daily on top of background medications. The dose of valsartan was force-titrated up to 320 mg.
A total of 152 patients were randomized (V ¼ 70, P ¼ 82). Most patients had well-controlled hypertension
(V ¼ 91.2%, P ¼ 89.0%) (mean baseline systolic BP 130 mmHg) and .50% were receiving an angiotensin-convert-
ing enzyme inhibitor and/or beta-blocker (V ¼ 57.4%, P ¼ 54.9%). The mean ejection fraction at baseline was 70.48%
in the placebo group (n ¼ 64) and 71.52% in the valsartan group (n ¼ 79). Valsartan had no signiﬁcant effect on exer-
cise time (primary variable), gas exchange variables, 6 min walk test distance, exertion-related symptoms, brain
natriuretic peptide levels, echocardiographic parameters, or quality-of-life scores. Valsartan signiﬁcantly lowered
peak exercise systolic BP (213.1 mmHg vs. placebo; P , 0.001) and improved ratings of perceived exertion (Borg
score) (20.69 vs. placebo; P ¼ 0.008).
Conclusion In this population, which predominantly included patients with well-controlled hypertension and symptomatic HFPEF,
addition of valsartan did not increase exercise time within 14 weeks. However, valsartan 320 mg reduced blood
pressure and improved symptoms of perceived exertion (Borg score) during exercise and was generally well-
tolerated.
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Heart failure with preserved ejection fraction (HFPEF), (previously
known as diastolic heart failure) arises from increased resistance
to ﬁlling of the ventricles, leading to symptoms of pulmonary and
systemic congestion.
1 The primary functional abnormalities of
HFPEF include impaired active left-ventricular relaxation and
increased passive stiffness. Among individuals with heart failure, the
prevalence of HFPEF has been reported to range from 13 to 74%,
which reﬂects the lack of a uniform deﬁnition of the condition.
2,3
Risk factors for HFPEF include increasing age, female gender, hyper-
tension, diabetes, obesity, coronary artery disease, and chronic
kidney disease.
4 Like systolic heart failure, HFPEF is associated with
considerable morbidity and mortality
5 and the risk of adverse
outcome increases with the severity of diastolic dysfunction.
6
Patients with HFPEF have increased activation of the renin–angio-
tensin–aldosterone system (RAAS), which contributes to the patho-
genesis and progression of the condition.
7 Angiotensin-converting
enzyme inhibitors (ACE-Is) and angiotensin receptor blockers
(ARBs) have demonstrated beneﬁcial effects in animal models of
HFPEF,
8,9 but in human studies no medication has shown a mortality
beneﬁt. Both ACE-Is and ARBs may decrease hospitalizations in
HFPEF, however the beneﬁts with ACE-Is may not be sustained
over a year.
10,11 Short-duration studies suggest that these agents
may have beneﬁcial effects on exercise tolerance, the hypertensive
response to exercise, and quality of life (QoL).
12–14These improve-
ments were observed after 2 weeks to 6 months of treatment and
are believed to be mediated through blockade of the effects of
angiotensin II, the levels of which are elevated during exercise.
15
Increases in angiotensin II during exertion may exacerbate diastolic
dysfunction, and therefore limit exercise tolerance, by elevating
blood pressure and impairing left-ventricular relaxation.
16
Valsartan is a highly selective ARB indicated for the treatment of
hypertension, heart failure, and left-ventricular failure following
myocardial infarction.
17 Administration of valsartan to rats with
HFPEF improved function and prolonged survival
9 and in a small
clinical study (n ¼ 24), valsartan improved the impaired left-
ventricular diastolic function of hypertensive patients.
18
The primary objective of the present study was to determine
whether valsartan could improve treadmill exercise time, in
patients with symptomatic HFPEF, compared with placebo.
Methods
The study protocol was approved by the Independent Ethics Commit-
tee for each centre, and the study was conducted in accordance with
the ethical principles of the Declaration of Helsinki. All patients pro-
vided written informed consent.
Patients
Patients were  21 years of age and had the following characteristics:
symptoms of breathlessness on exertion (based on patient question-
ing) with normal lung function at rest, an extrapolated maximum
oxygen consumption (EMOC) and/or peak oxygen consumption
,85% of the age-corrected normal value on cardiopulmonary exercise
testing, preserved systolic function (ejection fraction  40%) with evi-
dence of diastolic dysfunction on echocardiography ( 1 of the follow-
ing: abnormal ﬂow propagation velocity, prolongation of isovolumic
relaxation time, E/A ratio reversal, and abnormal E deceleration
time), and ability to exercise for  3 min on a treadmill. The ejection
fraction criterion of  40% is similar to that used in other trials in
HFPEF including the CHARM-Preserved trial and PEP-CHF.
10,11
Exclusion criteria are given in Table 1.
Study design
Thiswasaninvestigator-initiatedmulticentre,randomized,double-blind,
placebo-controlled, parallel-group study. Following a screening period
ofupto13weeksduration,eligiblepatientswererandomizedatbaseline
(Visit 2) in a 1:1 ratio to receive either valsartan 80 mg once daily or
matching placebo. Use of other ARBs as concomitant medication was
prohibited, but other background medications (e.g. diuretics, calcium
channel blockers) were allowed and continued throughout the study.
Angiotensin-converting enzyme inhibitors and beta-blockers were per-
mitted,althoughtherapywastobemaintainedatthesamelevelthrough-
out the study and no new treatment with one of these drugs was
permitted during the trial. Eligible patients were allocated to either the
active treatment group or the placebo group according to a stratiﬁed
randomization process in order to minimize the differences between
study groups. Stratiﬁcation was based on exercise test time at Visit 2
divided into sections of: 3–6 min, .6 min to 9 min, and .9 min, each
stratum being randomized in blocks of 4.
Study medication was force-titrated between days 5 and 14 (Visit 3)
to valsartan 160 mg daily or matching placebo, and between days 10
and 28 (Visit 4) to valsartan 320 mg daily or matching placebo.
Up-titration occurred provided the current dose was adequately toler-
ated. Down-titration occurred for any of the following: evidence of per-
sistent symptomatic hypotension, systolic blood pressure ,100 mmHg
or decrease of .40 mm Hg from baseline, creatinine increase of .50%
from baseline, or if the investigators judged the given dose level as
potentially harmful to the patient. A safety evaluation was performed
between days 15 and 42 (Visit 5). After the dose-titration period,
patients received their maximum tolerated dose through to the end
of the studyat week 14 (+7 days) (Visit 6). To maintain blinding, valsar-
tan and placebo capsules were identical in appearance.
Efﬁcacy assessments
Exercise testing using a modiﬁed Bruce protocol
19 was performed
during screening (pre-randomization), at baseline (randomization),
between days 15 and 42, and at the end of the study. Subjects had a
Table 1 Exclusion criteria
Uncontrolled hypertension (sitting systolic blood pressure
.160 mmHg or sitting diastolic blood pressure .100 mmHg)
Presence of clinically signiﬁcant asthma or chronic obstructive
pulmonary disease
Abnormal lung function (forced expiratory volume in 1 s [FEV1]/
forced vital capacity [FVC] ratio ,75%)
Treatment with  2 bronchodilators
Exercise limiting symptomatic angina
Haemodynamically signiﬁcant cardiac valvular disease
Documented evidence of systolic heart failure (ejection fraction
,40%, fractional shortening ,25%)
Uncontrolled atrial ﬁbrillation (.100 b.p.m. at rest)
History of myocardial infarction, percutaneous transluminal coronary
angioplasty,orcoronaryarterybypasswithinthe previous3 months
Use of ARBs within the previous 1 month
Effects of valsartan on exercise time in patients with HFPEF 981practice treadmill session during the pre-screening visit to demonstrate
that they were able to exercise for at least 3 min at baseline (Visit 2).
The electrocardiogram (ECG) was monitored continuously. Standing
blood pressure was recorded using a mercury sphygmomanometer
before starting exercise and immediately after stopping the treadmill.
During the exercise test, patients breathed through a valve that separ-
ated inspired and expired air. Measurements of oxygen consumption
(VO2), carbon dioxide production (VCO2), and minute ventilation
(VE BTPS) were obtained and averaged over 10 s. From these
measurements, the respiratory exchange ratio (RER) was determined.
Ratings of perceived exertion were made during every stage of the
exercise test using the Borg scale.
20
At baseline and at the end of the study, the 6 min walk test was per-
formed after the exercise testing was complete. The incidence of pre-
speciﬁed events (i.e. exertion-related symptoms of angina, dizziness,
dyspnoea, and fatigue) was determined. At the same timepoints,
blood samples were collected to determine the following neurohor-
mone levels: brain natriuretic peptide (BNP),
21 noradrenaline and
adrenaline,
22 plasma renin activity, aldosterone, and procollagen type
III amino-terminal peptide.
23 Samples for renin, aldosterone, and
natriuretic peptides were collected after 10 min of supine rest prior
to exercise testing. The Minnesota Living with Heart Failure
(MLHF)
24 and EuroQol questionnaires
25 were completed by patients
before any other assessments were done. Echocardiography was per-
formed during screening and at the end of the study. Patient and phys-
ician global assessments of efﬁcacy were made at the end of the study
(rated as very good, good, moderate, poor, or very poor).
Safety assessments
Safety was assessed via monitoring for adverse events (AEs), standard
clinical laboratory testing (haematology, blood chemistry, and urinaly-
sis), ECG recordings, routine physical examinations, and regular
measurement of vital signs. Patient and physician global assessments
of tolerability were made at the end of the study (rated as very
good, good, moderate, poor, or very poor).
Statistical methods
A sample size of 150 patients (128 with data available) was pre-
speciﬁed to provide 80% power to detect a difference in means of
1.25 min (i.e. an effect size of 0.5) using a two-group t-test with a two-
sided signiﬁcance level of 0.050. Sample-size calculations assumed a
common standard deviation (SD) of 2.5 min. The efﬁcacy analysis
was performed on the intent-to-treat (ITT) population, which included
all patients who received  1 dose of study medication and had base-
line efﬁcacy data and  1 post-baseline measurement. The safety popu-
lation included all patients allocated to treatment who received  1
dose of study medication.
Demographic and baseline characteristics were compared between
the two study groups using either the Wilcoxon two-sample test (con-
tinuous variables), x
2 test (categorical variables), or Fisher’s Exact test
(exertion-related symptoms during the 6 min walk test). The hypoth-
esis of no difference in mean change from baseline in exercise time
was tested using a two-factor analysis of covariance (ANCOVA),
with country, treatment, baseline ACE-Is use (yes/no), and baseline
beta-blocker use (yes/no) as factors and with baseline exercise time
as a covariate. The ‘endpoint’ measurement for each randomized
patient was the last post-randomization measurement carried
forward to the end of the study. Secondary efﬁcacy variables were ana-
lysed using the same ANCOVA model as described for the primary
analysis, with the exception of the incidence of exertion-related symp-
toms during the 6 min walk test and global assessment results, for
which Fisher’s Exact test was used. Exploratory analyses were per-
formed to assess the impact of treatment centre and baseline exercise
time on the primary efﬁcacy outcome. For these analyses, statistical
signiﬁcance was concluded if the 95% conﬁdence interval did not
include 0.
Figure 1 Patient disposition.
H.K. Parthasarathy et al. 982Results
Patients
Patient disposition is presented in Figure 1. Of the 166 patients
screened, 152 were randomized (70 valsartan, 82 placebo) and
147 completed the study (66 valsartan, 81 placebo). Of the
152 randomized patients, 87 (57.2%) were recruited at German
centres and 65 (42.8%) at UK centres. Within each country,
recruitment was dominated by one or two centres. At randomiz-
ation (Baseline Visit 2), 152 patients were stratiﬁed according to
their exercise time. In the  3–6 min stratum there were
19 patients (12.5%), 31 patients (20.4%) in the .6–9min
stratum, and 102 (67.1%) patients in the .9 min stratum. More
patients were randomized into the placebo arm than the valsartan
arm. It is likely that this was due to the majority of centres enroling
only a small number of patients; only three centres enrolled more
than seven patients. Consequently there were incomplete blocks,
which were exacerbated by the stratiﬁcation of patients by
baseline exercise time. The ITT population comprised 150 patients
(68 valsartan, 82 placebo) and the safety population 152 patients
(70 valsartan, 82 placebo).
The two study groups were well balanced with respect to
demographic and baseline characteristics (Table 2). The only
statistically signiﬁcant difference was a slightly greater mean body
mass index in the valsartan group (31.0 vs. 29.3 kg/m
2 for
placebo; P ¼ 0.010). Half the patients were male, and 94.7%
were Caucasian. The mean age was 62.1 years. The majority of
patients had a history of hypertension (90.0%). However,
mean sitting blood pressures were well controlled with a mean
baseline of 130.2/76.3 mmHg in the valsartan group and 130.1/
75.2 mmHg in the placebo group. Overall 71.4% of patients had
cardiac disorders, in particular angina pectoris (15.7% valsartan,
14.6% placebo), myocardial infarction (14.3 vs. 20.7%), and atrial
ﬁbrillation (12.9 vs. 8.5%). Other concomitant diseases included
diabetes (22.1 vs. 14.6%) and left ventricular hypertrophy (15.7
vs. 13.4%). A substantial proportion of patients were receiving an
ACE-I and/or beta-blocker (57.4% valsartan, 54.9% placebo). A
history of dihydropyridine calcium channel blocker and thiazide
diuretic use was reported for 28.6 and 20.0% of valsartan recipi-
ents, respectively, and 26.8 and 30.5% of placebo recipients,
respectively. At baseline, ﬁndings were similar between the study
groups for spirometry, exercise test, 6 min walk test (distance
and symptoms), and neurohormone levels. Exercise time at base-
line was 11.0 min in the valsartan group and 10.5 min in the
placebo group (Table 2). The mean duration of treatment was
13.9 weeks for valsartan recipients and 13.7 weeks for placebo
...............................................................................................................................................................................
Table 2 Demographic and baseline characteristics
Variable Valsartan (n 5 68) Placebo (n 5 82) P-value
Age, years 61.0 (11.5) 63.1 (10.3) 0.444
Age group, n (%) 0.651
,65 years 39 (57.4) 44 (53.7)
 65 years 29 (42.6) 38 (46.3)
Gender, n (%) 1.000
Male 34 (50.0) 41 (50.0)
Female 34 (50.0) 41 (50.0)
Race, n (%) 0.886
Caucasian 65 (95.6) 77 (93.9)
Other 3 (4.4) 5 (6.1)
BMI, kg/m
2 31.0 (4.7) 29.3 (5.3)
a 0.010
Medical history, n (%)
Hypertension 62 (91.2) 73 (89.0) 0.662
Diabetes 15 (22.1) 12 (14.6) 0.239
Atrial ﬁbrillation 11 (16.2) 8 (9.8) 0.239
Concomitant medication, n (%)
ACE-inhibitor 28 (41.2) 31 (37.8) 0.674
Beta-blocker 23 (33.8) 28 (34.1) 0.967
ACE-inhibitor and/or beta-blocker 39 (57.4) 45 (54.9) 0.761
FEV1, L 2.5 (0.8) 2.4 (0.7) 0.493
FVC, L 2.9 (0.8) 3.0 (0.9) 0.914
Exercise time, min 11.0 (3.7) 10.5 (3.9) 0.396
RPE (Borg scale) 5.2 (1.4) 5.2 (1.8) 0.984
Distance walked during 6 min walk test, m 471.6 (105.3) 471.6 (114.2) 0.767
Values are expressed as means (standard deviation) unless otherwise stated.
ACE, angiotensin-converting enzyme; BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RPE, rating of perceived exertion.
an ¼ 81.
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tered to 82.9% of patients in each study group.
Exercise time (primary efﬁcacy variable)
None of the study population had inducible ischaemia during exer-
cise. Least-squares mean increases from baseline to endpoint in
exercise time, the primary efﬁcacy variable, were observed in
both study groups (Table 3), with the improvement on placebo
(1.24 min) being slightly better than on valsartan (0.96 min). The
between-group difference (valsartan minus placebo) was
20.28 min [95% conﬁdence interval (CI): 20.84, 0.29] (P ¼
0.336). To explore the effect of unbalanced recruitment, explora-
tory analyses were performed. These showed that results were
consistent across all centres, with the exception of pooled UK
centres 4, 5, and 6 (n ¼ 9 patients only) in which the placebo
group showed a signiﬁcantly greater response. Exploratory analysis
of the impact of baseline exercise time showed that, for patients
with baseline exercise time of  9 min, there was a trend (non-
signiﬁcant) toward greater response in the placebo group.
Further analysis looking into change from baseline in exercise
time against the change from baseline in maximum exercise SBP,
the maximum exercise SBP at study end and the maximum exer-
cise SBP at baseline did not show any signiﬁcant relationship.
During the study, an improvement in exercise time was
achieved by 69.1% of valsartan-treated patients and 72.0% of
placebo-treated patients. The percentages of patients who had a
deterioration in exercise time were also similar (26.5 and 24.4%
on valsartan and placebo, respectively).
Other variables derived from
exercise test
At the end of the study, no signiﬁcant differences were observed
between the study groups in least-squares mean changes from
baseline in EMOC, VO2, VCO2, VE BTPS, or RER at peak exercise
(Table 3). The least-squares mean reduction from baseline to end-
point in maximum systolic blood pressure was signiﬁcantly greater
in the valsartan group [between-group difference, 213.1 mmHg
(95% CI: 219.2, 27.0); P , 0.001] (Figure 2A). No signiﬁcant
between-group differences were found for maximum diastolic
blood pressure or maximum pulse rate. Least-squares mean
changes from baseline to endpoint in the maximum Borg score
showed a reduction (improvement) in the valsartan group and
an increase (deterioration) in the placebo group (between-group
difference, 20.69 [95% CI: 21.20, 20.18); P ¼ 0.008] (Figure 2B).
6 minute walk test
Treatment with valsartan and placebo was associated with
least-squares mean increases from baseline to week 14 in distance
on the 6 min walk test (15.6 and 12.7 m, respectively). The
between-group difference was 2.9 m (95% CI: 211.7, 17.4; P ¼
0.698). The incidence of exertion-related symptoms, including
...........................................
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Table 3 Least-squares mean changes from baseline to endpoint in total exercise test time and gas exchange variables at
peak exercise
Variable Mean (SD) LSM change (SEM) Difference (SEM)
a 95% CI P-value
Baseline Endpoint
Exercise time, min
Valsartan (n ¼ 68) 10.96 (3.73) 11.80 (3.62) 0.96 (0.22)
Placebo (n ¼ 82) 10.47 (3.88) 11.70 (3.29) 1.24 (0.20) 20.28 (0.29) 20.84, 0.29 0.336
EMOC, mL/kg/min
b
Valsartan (n ¼ 38) 533.71 (245.93) 566.56 (251.82) 4.63 (30.83)
Placebo (n ¼ 48) 614.04 (285.63) 642.56 (283.88) 19.09 (28.19) 214.46 (39.04) 292.14, 63.21 0.712
VO2, mL/kg/min
Valsartan (n ¼ 68) 17.83 (4.46) 17.84 (5.69) 20.17 (0.53)
Placebo (n ¼ 82) 17.68 (5.96) 18.80 (5.23) 0.85 (0.49) 21.02 (0.69) 22.39, 0.35 0.142
VCO2, mL/min
Valsartan (n ¼ 68) 18.06 (6.87) 18.59 (7.92) 0.18 (0.68)
Placebo (n ¼ 82) 18.97 (7.87) 19.71 (7.94) 0.56 (0.62) 20.38 (0.88) 22.13, 1.36 0.664
VE BTPS, L/min
Valsartan (n ¼ 68) 52.37 (15.33) 53.99 (18.34) 0.75 (1.83)
Placebo (n ¼ 82) 52.14 (16.41) 54.96 (19.01) 1.83 (1.69) 21.08 (2.41) 25.83, 3.68 0.655
RER
Valsartan (n ¼ 68) 1.06 (0.13) 1.40 (2.69) 0.38 (0.37)
Placebo (n ¼ 82) 1.09 (0.13) 1.44 (3.15) 0.43 (0.34) 20.05 (0.49) 21.02, 0.92 0.923
EMOC, extrapolated maximum oxygen consumption; LSM, least-squares mean; RER, respiratory exchange ratio; SD, standard deviation; SEM, standard error of the mean; VCO2,
carbon dioxide production; VE BTPS, minute ventilation; VO2, oxygen consumption.
aValsartan minus placebo.
bEMOC was assessed at German centres only.
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between the study groups (all P   0.317).
Neurohormone levels
As shown in Table 4, percent least-squares mean changes from
baseline to week 14 in plasma BNP and other neurohormone
levels did not differ signiﬁcantly between the study groups, with
the exception of the expected greater increase in plasma renin
activity and decrease in aldosterone in the valsartan group (P ¼
0.013 and P ¼ 0.015, respectively, vs. placebo).
Other secondary efﬁcacy variables
Echocardiographic parameters and QoL scores did not differ sig-
niﬁcantly between the study groups, with the exception of a
more favourable MLHF emotional score in the placebo group
(P ¼ 0.027) (Table 5). The mean ejection fraction at baseline was
70.48% in the placebo group (n ¼ 64) and 71.52% valsartan
group (n ¼ 79). There was no signiﬁcant change compared with
baseline in the ejection fraction in either group at the end of the
study. The percentage of patients with an overall echocardio-
graphic interpretation of ‘normal,’ in the opinion of the investi-
gators, increased from 1.5% at baseline to 9.0% at the end of the
study in the valsartan group compared with 0–1.2% in the
placebo group. Patient global assessments of efﬁcacy were com-
parable (P ¼ 0.202) between the study groups: 58.2% of patients
in the valsartan group and 50.0% in the placebo group rated treat-
ment as very good or good. Similar results were reported by
physicians.
Figure 2 Least-squares mean changes from baseline to end-
point in (A) maximum systolic blood pressure (SBP) and
maximum diastolic blood pressure (DBP) and (B) maximum
Borg score. Error bars denote standard error of the mean.
*P , 0.001 vs. placebo;
†P ¼ 0.008 vs. placebo.
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Table 4 Percent least-squares mean changes from baseline to week 14 in neurohormone levels
Variable Mean (SD) LSM Change (SEM) Ratio (SEM)
a 95% CI P-value
Baseline Endpoint
BNP, pg/mL
Valsartan 93.2 (80.2) (n ¼ 60) 94.0 (78.6) (n ¼ 61) 97.5 (110.8) (n ¼ 60)
Placebo 120.3 (119.5) (n ¼ 73) 109.9 (105.0) (n ¼ 74) 93.9 (109.9) (n ¼ 73) 103.9 (114.1) 80.0, 134.9 0.774
Noradrenaline, pg/mL
Valsartan (n ¼ 54) 529.1 (258.9) 538.5 (282.6) 94.8 (106.9)
Placebo (n ¼ 64) 621.1 (303.9) 589.1 (254.2) 100.4 (106.3) 94.4 (109.0) 79.6, 112.0 0.504
Adrenaline, pg/mL
Valsartan (n ¼ 54) 91.4 (231.6) 53.4 (50.7) 84.4 (108.2)
Placebo (n ¼ 64) 60.2 (42.9) 63.6 (59.3) 97.3 (107.5) 86.7 (110.7) 70.9, 106.0 0.161
PRA, ng/mL/h
Valsartan (n ¼ 61) 4.9 (10.6) 7.8 (10.9) 181.8 (122.5)
Placebo 4.0 (7.7) (n ¼ 71) 3.8 (7.6) (n ¼ 72) 93.1 (121.0) (n ¼ 71) 195.4 (130.5) 115.4, 331.0 0.013
Aldosterone, pg/mL
Valsartan 170.2 (101.0) (n ¼ 57) 134.9 (88.7) (n ¼ 59) 78.9 (107.3) (n ¼ 57)
Placebo 174.6 (113.3) (n ¼ 68) 169.9 (103.6) (n ¼ 70) 99.2 (106.7) (n ¼ 68) 79.5 (109.7) 66.2, 95.6 0.015
PIIINP, mg/mL
Valsartan (n ¼ 60) 3.3 (1.1) 3.3 (0.9) 98.3 (103.0)
Placebo (n ¼ 72) 3.5 (1.1) 3.6 (1.1) 104.4 (102.7) 94.1 (103.9) 87.2, 101.5 0.114
BNP, brain natriuretic peptide; PIIINP, procollagen type III amino-terminal peptide; PRA, plasma renin activity; SD, standard deviation; SEM, standard error of the mean.
aValsartan relative to placebo.
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Table 5 Least-squares mean changes from baseline to week 14 in echocardiographic parameters and quality-of-life
scores
Variable Mean (SD) LSM change (SEM) Difference
(SEM)
a
95% CI P-value
Baseline Endpoint
E/A ratio
Valsartan (n ¼ 61) 1.16 (0.85) 1.16 (0.73) 0.05 (0.06)
Placebo (n ¼ 79) 1.07 (0.68) 1.04 (0.44) 20.03 (0.05) 0.08 (0.07) 20.07, 0.23 0.277
Flow propagation
velocity, cm/s
Valsartan 37.18 (12.72) (n ¼ 51) 38.57 (13.42) (n ¼ 52) 5.00 (7.50) (n ¼ 51)
Placebo 37.64 (12.05) (n ¼ 66) 47.85 (69.44) (n ¼ 69) 12.11 (7.10) (n ¼ 66) 27.11 (9.55) 226.0, 11.82 0.458
IVRT, ms
Valsartan 103.63 (18.84) (n ¼ 64) 99.62 (17.27) (n ¼ 65) 24.48 (2.10) (n ¼ 64)
Placebo 103.23 (23.06) (n ¼ 81) 101.38 (20.69) (n ¼ 82) 22.76 (1.90) (n ¼ 81) 21.72 (2.72) 27.10, 3.66 0.528
LVIDD, cm
Valsartan 5.08 (0.88) (n ¼ 64) 5.08 (0.79) (n ¼ 65) 0.01 (0.06) (n ¼ 64)
Placebo 5.16 (0.71) (n ¼ 79) 5.16 (0.72) (n ¼ 80) 0.02 (0.05) (n ¼ 79) 20.01 (0.07) 20.16, 0.14 0.886
LVIDS, cm
Valsartan 3.35 (0.85) (n ¼ 64) 3.32 (0.81) (n ¼ 65) 20.01 (0.07) (n ¼ 64)
Placebo 3.33 (0.75) (n ¼ 79) 3.46 (0.75) (n ¼ 80) 0.15 (0.06) (n ¼ 79) 20.15 (0.09) 20.33, 0.02 0.077
Left atrial size, cm
Valsartan (n ¼ 66) 4.24 (0.71) 4.26 (0.66) 0.02 (0.06)
Placebo 4.15 (0.68) (n ¼ 77) 4.05 (0.69) (n ¼ 79) 20.12 (0.05) (n ¼ 77) 0.14 (0.08) 20.00, 0.29 0.055
Left ventricular mass, g
Valsartan 232.33 (88.45) (n ¼ 55) 223.74 (74.49) (n ¼ 57) 28.87 (6.76) (n ¼ 55)
Placebo 213.58 (69.45) (n ¼ 70) 219.87 (75.75) (n ¼ 74) 0.16 (6.30) (n ¼ 70) 29.02 (8.88) 226.6, 8.55 0.311
E deceleration time, ms
Valsartan 248.8 (63.45) (n ¼ 66) 237.9 (65.13) (n ¼ 67) 26.51 (5.65) (n ¼ 66)
Placebo 230.7 (50.67) (n ¼ 81) 238.8 (52.32) (n ¼ 82) 5.10 (5.18) (n ¼ 81) 211.6 (7.46) 226.3, 3.13 0.122
Ejection fraction%
Valsartan 70.48 (11.43) (n ¼ 64) 70.76 (12.19) (n ¼ 65) 20.39 (1.35) (n ¼ 64)
Placebo 71.52 (12.08) (n ¼ 79) 68.58 (11.77) (n ¼ 80) 23.14 (1.23) (n ¼ 79) 2.75 (1.76) 20.73, 6.22 0.120
MLHF
Overall score
Valsartan (n ¼ 67) 27.02 (20.47) 23.54 (21.36) 23.14 (1.58)
Placebo 23.49 (19.18) (n ¼ 81) 19.54 (14.71) (n ¼ 82) 24.85 (1.45) (n ¼ 81) 1.71 (2.07) 22.38, 5.81 0.409
Physical dimension
score
Valsartan (n ¼ 67) 13.72 (9.39) 11.65 (9.66) 21.72 (0.81)
Placebo 12.14 (9.87) (n ¼ 81) 10.11 (7.71) (n ¼ 82) 22.28 (0.74) (n ¼ 81) 0.55 (1.06) 21.53, 2.64 0.601
Emotional score
Valsartan (n ¼ 67) 5.40 (5.94) 5.11 (6.55) 20.26 (0.48)
Placebo 5.09 (5.72) (n ¼ 81) 3.63 (4.18) (n ¼ 82) 21.67 (0.44) (n ¼ 81) 1.41 (0.63) 0.16, 2.66 0.027
ED-5D (visual analog
scale)
Valsartan (n ¼ 66) 71.23 (14.43) 71.06 (16.88) 20.11 (1.87)
Placebo 68.49 (17.40) (n ¼ 81) 70.99 (17.11) (n ¼ 82) 1.26 (1.71) (n ¼ 81) 21.37 (2.45) 26.21, 3.47 0.577
A, atrial ﬁlling velocity; E, early ﬁlling velocity; ED-5D, EuroQol questionnaire; IVRT, isovolumic relaxation time; LVIDD, left-ventricular end diastolic dimension in diastole; LVIDS,
left-ventricular end diastolic dimension in systole; MLHF, Minnesota Living with Heart Failure, SD, standard deviation; SEM, standard error of the mean.
aValsartan minus placebo.
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Adverse event were reported for 77.1 and 72.0% of patients in the
valsartan and placebo groups, respectively. The most frequently
reported events were dizziness (14.3% valsartan, 17.1% placebo)
and fatigue (10.0%, 11.0%). Valsartan recipients had a slightly
higher incidence of dyspnoea (12.9 vs. 7.3%), cough (7.1 vs.
3.7%), and hypotension (7.1 vs. 1.2%). The majority of AEs were
mild or moderate in severity. Adverse events led to premature
study discontinuation for two valsartan-treated patients (hypoten-
sion, mesothelioma). The patient with hypotension was discontin-
ued when his blood pressure decreased (from 120.0/77.0 mmHg at
screening) to 85.3/53.3 mmHg on day 83. This event was believed
to be related to the study medication. At the patient’s ﬁnal evalu-
ation on day 118 (after about 1 month off treatment), blood
pressure was 107.3/73.0 mmHg. There were no deaths during
the study. Ten patients experienced serious AEs (four valsartan,
six placebo). However, none was judged by the investigators to
be related to study medication. Based on vital signs evaluations,
mean systolic blood pressure was reduced from baseline to
study end by 4.3 mmHg in the valsartan group while it increased
over the same time period by 1.7 mmHg in the placebo group
(P ¼ 0.021). Changes in mean pulse rate were negligible. Patient
global assessments of tolerability were similar (P ¼ 0.415) for
both study groups: 94.0% of patients in the valsartan group and
92.7% in the placebo group rated treatment as very good or
good. Similar results were reported by physicians. Other safety
ﬁndings were unremarkable.
Discussion
Treatment with valsartan did not signiﬁcantly improve exercise
time in this population which predominantly included patients
with hypertension (90.0%) with good BP control and sympto-
matic HFPEF. In our study, valsartan reduced mean resting systolic
blood pressure from baseline by 6 mmHg at study end and peak
exercise systolic blood pressure by about 13 mmHg over placebo,
despite the extensive use of background medications (e.g. ACE-Is,
beta-blockers). We believe that this is an important ﬁnding
because increases in this parameter are associated with negative
long-term cardiovascular outcomes. Speciﬁcally, exercise-induced
elevations in systolic blood pressure have been associated with
cardiac remodelling,
26with the development of future hyperten-
sion,
27 and with increased cardiovascular mortality
27,28 and
stroke.
29
The Borg rating scale results suggest that patients felt better
during valsartan treatment, but patient QoL scores did not
improve. We cannot explain this inconsistency but it could be
due to the small sample size or the timing of data collection.
Ratings of perceived exertion were made during every stage of
the exercise test, whereas QoL questionnaires were completed
before any other assessments. Treatment with valsartan was
associated with the expected changes in plasma renin activity
and aldosterone levels, providing evidence of angiotensin II type
1 receptor blockade.
There was no BNP requirement for entry into the study. Brain
natriuretic peptide is released from the ventricle in response to
volume expansion and pressure overload, and levels are elevated
in HFPEF.
30 Nonetheless, while a low BNP value is highly effective
for ruling out heart failure, a high value is only a fair marker of the
disease and may be associated with other conditions including
renal failure, pulmonary hypertension, and pulmonary embolism.
The diagnostic value of BNP testing is likely to be in identifying indi-
viduals who require further testing with echocardiography. In our
study, the lack of effect of valsartan on lowering BNP is inconsist-
ent with previous ﬁndings in patients with heart failure and left ven-
tricular ejection fraction ,40%.
31,32 However, this may be related
to the fact that the baseline BNP levels in those studies were 2–
2.5-fold greater than those of the valsartan recipients in our study.
This again points out that our population had relatively mild
HFPEF.
33 In addition, the concomitant use of ACE-Is and
beta-blockers has been shown to attenuate the effect of valsartan
on this parameter.
31
Unbalanced recruitment within the study centres did not appear
to contribute to our results. Recruitment was dominated by one
or two centres in each country, but exploratory analysis indicated
that the overall ITT result was not substantially inﬂuenced by this
factor. One might have expected a greater beneﬁt of valsartan over
placebo in patients with lower baseline exercise times ( 9 min),
but this was not the case. The reason for the lack of a signiﬁcant
effect appears to be due to the treatment difference being
smaller than planned and in the opposite direction to what was
anticipated rather than an incorrect assumption of SD at planning.
Valsartan has demonstrated positive effects on diastolic function
in two previous randomized, double-blind studies. The earlier
study included patients with hypertension and no evidence of
left ventricular hypertrophy.
18 A subgroup of 12 patients with
impaired left-ventricular peak ﬁlling rate at baseline had a signiﬁcant
improvement in this parameter, both at rest and at peak exercise
(P , 0.05), after 4 weeks of treatment with valsartan 80–160 mg
daily. The Valsartan In Diastolic Dysfunction (VALIDD) study
included 384 patients with hypertension (mean systolic blood
pressure of 144 mmHg) and HFPEF.
34 Placebo or valsartan
160–320 mg daily were administered for up to 38 weeks, in
addition to other antihypertensive agents that did not inhibit the
RAAS. The groups demonstrated comparable reductions in
blood pressure (P ¼ NS). Signiﬁcant improvement in diastolic
relaxation velocity, the primary endpoint, was observed irrespec-
tive of the type of antihypertensive agent used (P , 0.001 for
both groups). Improvements in isovolumetric relaxation time and
systolic longitudinal velocity were signiﬁcantly greater with valsar-
tan treatment (P , 0.05).
However, these patients had varying comorbidities (e.g. ,2%
had atrial ﬁbrillation in VALIDD vs. nearly 13% in the present
study) and were receiving different background therapies (e.g.
none on ACE-Is in VALIDD vs. 39% in the present study).
Limitations
It is possible that the criteria used for patient selection may not
have been appropriate for identifying the patients who would
beneﬁt most from valsartan therapy. It is also possible that some
patients studied may have been in the ‘grey zone’ between symp-
tomatic hypertension and heart failure. However we believe that
our patient population satisﬁed well-deﬁned criteria for heart
Effects of valsartan on exercise time in patients with HFPEF 987failure including presence of symptoms of breathlessness and peak
VO2 , 85% predicted in the presence of normal lung function.
35,36
A speciﬁc duration of HFPEF was not required for study entry, and
such data were not collected. Patients with a longer history and
more severe degree of HFPEF may have been better suited for
enrolment as might subjects with an elevated BNP at rest.
The relatively short study period should be taken into consider-
ation. However, there are reports of signiﬁcant improvement in
exercise systolic blood pressure, exercise tolerance (modiﬁed
Bruce protocol), and QoL (MLHF) in patients with diastolic dys-
function and exaggerated BP response (.200 mmHg), after treat-
ment with other ARBs for durations as short as 2 weeks.
12,14
However, these studies were both done in small groups of patients
(n ¼ 20 and 40) and the patients had an exaggerated BP
(.200 mmHg) response during exercise as a pre-requisite for
study entry. In our study population, the mean peak systolic exer-
cise BP was lower (171 mmHg). Moreover, in these studies
patients had a higher resting systolic blood pressure at entry
(140–143 mmHg) compared with our study.
Exercise blood pressure and Borg scale are secondary out-
comes. The beneﬁt of valsartan seen on these parameters is not
reﬂected in the other outcomes studied. However, we believe
that this data adds important information to the sparse data avail-
able in this population of HFPEF.
Conclusion
In this population, which predominantly included patients with
well-controlled hypertension who had symptomatic HFPEF, the
addition of valsartan did not increase exercise time within a 14
week treatment period. Valsartan signiﬁcantly improved ratings
of perceived exertion (Borg scale), a secondary endpoint of the
study, and was well tolerated at the 320 mg dose. Further improve-
ment in exercise capacity in this relatively mild HF population may
not be expected by adding an ARB for a short duration.
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